Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In CanadaBenzinga • 10/07/26
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement TherapyPRNewsWire • 10/07/26
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/23/26
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPRNewsWire • 09/14/26
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire • 09/10/26
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154PRNewsWire • 06/04/26
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual MeetingPRNewsWire • 05/19/26
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business OfficerGlobeNewsWire • 05/19/26
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 04/06/26
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum DepressionPRNewsWire • 04/02/26
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)PRNewsWire • 02/18/26
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PRNewsWire • 01/20/26
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PRNewsWire • 01/12/26
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PRNewsWire • 11/18/25